X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3320) 3320
triazines - therapeutic use (2888) 2888
male (2123) 2123
female (1787) 1787
animals (1350) 1350
adult (1329) 1329
lamotrigine (1247) 1247
anticonvulsants - therapeutic use (1239) 1239
middle aged (1036) 1036
triazines - pharmacology (913) 913
clinical neurology (896) 896
triazines - adverse effects (846) 846
treatment outcome (792) 792
pharmacology & pharmacy (724) 724
epilepsy - drug therapy (691) 691
triazines - administration & dosage (636) 636
epilepsy (605) 605
adolescent (585) 585
psychiatry (561) 561
aged (559) 559
anticonvulsants - adverse effects (522) 522
drug therapy, combination (498) 498
mice (483) 483
vardenafil dihydrochloride (455) 455
dose-response relationship, drug (446) 446
double-blind (439) 439
child (435) 435
rats (428) 428
neurosciences (410) 410
anticonvulsants (399) 399
bipolar disorder - drug therapy (394) 394
piperazines - therapeutic use (382) 382
imidazoles - therapeutic use (379) 379
valproic acid - therapeutic use (371) 371
antiepileptic drugs (354) 354
triazines - pharmacokinetics (345) 345
efficacy (341) 341
carbamazepine (319) 319
analysis (305) 305
carbamazepine - therapeutic use (302) 302
double-blind method (298) 298
erectile dysfunction - drug therapy (297) 297
sulfones - therapeutic use (281) 281
triazines - chemistry (275) 275
time factors (255) 255
neurology (248) 248
oncology (246) 246
phosphodiesterase inhibitors - therapeutic use (243) 243
drug interactions (242) 242
bipolar disorder (239) 239
drug therapy (238) 238
child, preschool (237) 237
fructose - analogs & derivatives (232) 232
triazines - blood (229) 229
anticonvulsants - administration & dosage (224) 224
anticonvulsants - pharmacology (222) 222
sildenafil citrate (220) 220
seizures (219) 219
pharmacokinetics (218) 218
young adult (215) 215
antineoplastic agents - therapeutic use (210) 210
drug administration schedule (206) 206
antimanic agents - therapeutic use (205) 205
clinical trials as topic (204) 204
drugs (200) 200
triazines (197) 197
tadalafil (196) 196
fructose - therapeutic use (194) 194
therapy (194) 194
care and treatment (190) 190
anticonvulsants - pharmacokinetics (189) 189
erectile dysfunction (186) 186
toxicology (183) 183
urology & nephrology (181) 181
retrospective studies (172) 172
topiramate (172) 172
children (171) 171
antipsychotic agents - therapeutic use (168) 168
biochemistry & molecular biology (165) 165
disease models, animal (165) 165
research (164) 164
valproate (163) 163
vardenafil (163) 163
prospective studies (162) 162
amines (161) 161
gabapentin (161) 161
monotherapy (161) 161
cancer (160) 160
pregnancy (160) 160
cyclohexanecarboxylic acids (157) 157
follow-up studies (149) 149
administration, oral (146) 146
sildenafil (146) 146
safety (144) 144
acetates - therapeutic use (143) 143
anticonvulsants - blood (141) 141
coccidiostats - therapeutic use (141) 141
depression (140) 140
medicine, general & internal (139) 139
randomized controlled trials as topic (139) 139
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4106) 4106
German (84) 84
Russian (61) 61
French (43) 43
Spanish (43) 43
Japanese (37) 37
Chinese (29) 29
Polish (25) 25
Hungarian (13) 13
Dutch (10) 10
Danish (7) 7
Italian (6) 6
Norwegian (6) 6
Czech (5) 5
Portuguese (4) 4
Finnish (2) 2
Hebrew (2) 2
Swedish (2) 2
Afrikaans (1) 1
Bulgarian (1) 1
Korean (1) 1
Romanian (1) 1
Slovak (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet neurology, ISSN 1474-4422, 2011, Volume 10, Issue 7, pp. 609 - 617
Journal Article
Journal Article
Epilepsia (Copenhagen), ISSN 0013-9580, 2017, Volume 58, Issue 10, pp. 1734 - 1741
Summary Objective Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE‐HS) is a common epilepsy syndrome that is often poorly controlled by... 
Drug response | Efficacy | Adverse drug reactions | Retention | Seizure freedom | CONTROLLED-TRIAL | REFRACTORY EPILEPSY | PROGNOSIS | LOCALIZATION-RELATED EPILEPSY | TOPIRAMATE | RETENTION RATES | NATURAL-HISTORY | CLINICAL NEUROLOGY | THERAPY | LAMOTRIGINE | RESISTANT EPILEPSY | Pregabalin - therapeutic use | Triazines - therapeutic use | Humans | Middle Aged | Epilepsy, Temporal Lobe - drug therapy | Epilepsy, Temporal Lobe - physiopathology | Male | Sclerosis | Young Adult | Amines - therapeutic use | Vision Disorders - chemically induced | Adult | Female | Valproic Acid - therapeutic use | Retrospective Studies | gamma-Aminobutyric Acid - therapeutic use | Epilepsy, Temporal Lobe - pathology | Databases, Factual | Diplopia - chemically induced | Cyclohexanecarboxylic Acids - therapeutic use | Carbamazepine - analogs & derivatives | Vertigo - chemically induced | Dizziness - chemically induced | Anticonvulsants - therapeutic use | Carbamazepine - therapeutic use | Treatment Outcome | Hippocampus - pathology | Lethargy - chemically induced | Fructose - therapeutic use | Fructose - analogs & derivatives | Vigabatrin - therapeutic use | Adolescent | Aged | Ataxia - chemically induced | Benzodiazepines - therapeutic use | Medical research | Care and treatment | Anticonvulsants | Medicine, Experimental | Temporal lobe epilepsy | Seizures (Medicine) | Comparative analysis | Topiramate | Temporal lobe | Gabapentin | Epilepsy | Clinical trials | Valproic acid | Antiepileptic agents | Carbamazepine | Vertigo | Oxcarbazepine | Convulsions & seizures | Drowsiness | Ataxia | Hippocampus | Lamotrigine
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
2005, Volume 65, Issue 12, 30
The field of erectile dysfunction (ED) has been revolutionised over the last two decades. Several treatment options are available today, most of which are... 
Phosphodiesterase IV inhibitors | Erectile dysfunction | Erectile devices | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | INFLATABLE PENILE PROSTHESIS | PHOSPHODIESTERASE TYPE-5 INHIBITOR | SILDENAFIL CITRATE VIAGRA((R)) | RADICAL RETROPUBIC PROSTATECTOMY | INTRACAVERNOUS ALPROSTADIL ALFADEX | INTRAURETHRAL PROSTAGLANDIN E-1 | PHARMACOLOGY & PHARMACY | SPINAL-CORD-INJURY | TERM MECHANICAL RELIABILITY | TOXICOLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | Phosphodiesterase Inhibitors - therapeutic use | Sulfones - therapeutic use | Phentolamine - adverse effects | Phentolamine - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Triazines - therapeutic use | Vasodilator Agents - therapeutic use | Humans | Dopamine Agonists - therapeutic use | Sulfones - adverse effects | Male | Dopamine Agonists - adverse effects | Apomorphine - therapeutic use | Apomorphine - adverse effects | Contraindications | Patient Satisfaction | Sildenafil Citrate | Penis - drug effects | Purines | Regional Blood Flow - drug effects | Alprostadil - therapeutic use | Erectile Dysfunction - drug therapy | Erectile Dysfunction - therapy | Treatment Failure | Imidazoles - therapeutic use | Papaverine - therapeutic use | Carbolines - therapeutic use | Penis - blood supply | Carbolines - adverse effects | Papaverine - adverse effects | Penile Prosthesis | Constriction | Administration, Oral | Imidazoles - adverse effects | Alprostadil - adverse effects | Piperazines - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Tadalafil | Vardenafil Dihydrochloride | Triazines - adverse effects | Vasodilator Agents - adverse effects | Vasodilator Agents - administration & dosage | Drug Combinations
Book Review
Schizophrenia Bulletin, ISSN 0586-7614, 09/2012, Volume 38, Issue 5, pp. 1003 - 1011
Journal Article
Cancer, ISSN 1097-0142, 2019, Volume 125, Issue 18, pp. 3121 - 3130
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by... 
acute myeloid leukemia (AML) | clinical trials | complete remission | measurable residual disease (MRD) | Triazines - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Decitabine | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Transplantation, Homologous | Pyrrolidines - therapeutic use | Neoplasm, Residual | Molecular Diagnostic Techniques | Flow Cytometry | Aminopyridines - therapeutic use | Azacitidine | Cytogenetic Analysis | Leukemia, Myeloid, Acute - therapy | Triazoles - therapeutic use | Hydrazines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Hematopoietic Stem Cell Transplantation | In Situ Hybridization, Fluorescence | Nivolumab - therapeutic use | Enzyme Inhibitors - therapeutic use | Remission Induction | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Agents, Immunological - therapeutic use | Lenalidomide - therapeutic use | Protein Kinase Inhibitors - therapeutic use | para-Aminobenzoates - therapeutic use | Aniline Compounds - therapeutic use | Immunologic Factors - therapeutic use | AML | PROGNOSTIC IMPACT | GEMTUZUMAB OZOGAMICIN | HEMATOPOIETIC-CELL TRANSPLANTATION | RISK STRATIFICATION | IMPROVE OUTCOMES | RELAPSE | ONCOLOGY | FLOW-CYTOMETRY | DIRECTED THERAPY | Flow cytometry | Myeloid leukemia | Leukemia | Medical treatment | Health risks | Clinical trials | Transplantation | Patients | Hemopoiesis | Risk assessment | Cytogenetics | Remission | Acute myeloid leukemia
Journal Article